Salute e Benessere
Next-Generation Cancer Diagnostics Market Forecast 2015-2025 Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies
Our 176-page report provides 87 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in the growing next-generation cancer diagnostics market.
• In addition to revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT analysis), product profiles and commercial developments.
• Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Keith Cannon , Executive Vice President,
Aviva Biosciences
- Nobuyoshi Katagiri , Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Along with revenue prediction for the overall world market, you will find revenue forecasts to 2025 for the following submarkets:
- Advanced PCR Techniques
- In Situ Hybridisation
- Circulating Tumour Cells
- Microarray
- Next-Generation Sequencing
Our investigation discusses what stimulates and restrains business. You will understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.
Our analysis also divides the main global forecast into geographical markets.
You will discover individual revenue forecasts for leading national markets from 2015-2025:
- US
- Japan
- EU5 ( Germany , France , UK,
Italy and Spain ) as a group
- China
- India
- Brazil
- Russia
- Rest of the World
There will be growth in established developed markets and in developing countries. Our analyses show that China , in particular, will continue to achieve high revenue growth to 2025. Greater uptake of existing technology and products worldwide will also stimulate the industry and market.
Overall world revenue for next-generation cancer diagnostics will reach
$1.6bn in 2015, our work calculates. We predict strong revenue growth through to 2025. Market entry of NGS and CTCs together with increasing demand from emerging markets will increase sales to 2025.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Our work identifies which organisations that hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. See visiongain's analysis of the leading companies developing the most innovative cancer diagnostic technologies, including these:
- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Thermo Fisher Scientific
- Agilent Technologies
- Hologic
- Illumina
- Myriad Genetics
Our new report discusses the issues and events affecting the next-generation cancer diagnostics market. You will find discussions, including qualitative analyses:
- Savings that could be made with earlier screening and diagnosis
- Increasing prevalence of cancer
- Increasing awareness of molecular cancer diagnostics
- Explosion in genomic and proteomic information
- The trends in personalised medicine
- The increasing adoption of companion diagnostics
- The advent of innovative diagnostic methods
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
In summary, our 176-page report provides you with the following knowledge:
- discover the industry's prospects, finding the most lucrative places for investments and revenues
- US, EU5,
Japan , China ,
Brazil , Russia and Rest of the World
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the next-generation cancer diagnostics market and leading companies. You find data, trends and predictions.
Buy our report today . Avoid missing out - order our report now.
454 Life Sciences
Abbott Laboratories
AbbVie
AbVitro
Advanced Cell Diagnostics
Advanced Liquid Logic
Affymetrix
Agendia
Agilent Technologies
Ambry
Amgen
Annoroad
Applied Biosystems
ARCH Venture Partners
AstraZeneca
Atossa Genetics
AvanSci
Aviva Biosciences
BD
Berry Genomics
BGI
Bina Technologies
Biobase
Biochain
BioFluidica
BioMarin Pharmaceutical
bioMérieux
Bio-Rad
BioServe India
BlueGnome
Bristol- Myers Squibb
Bruker
Cancer Genetics
Cepheid
CLC bio
CompanionDx
Counsyl
Crescendo Bioscience
CytoTrack
Dako
DakoCytomation
Danaher
DiagnoCure
DxS
Eli Lilly
Enzymatics
Epic Sciences
Epicentre Technologies
Epigenomics
Exact Sciences
Fidelity Management
Fluidigm
Fluxion
GeneDx
Genentech
Genia Technologies
Genomic Health
Gen-Probe
GnuBio
HalioDX
Hitachi High-Technologies
Hologic
Idaho Technology
IGEN International
Illumina
Ingenuity Systems
Insilico Medicine
Invitae
Invitrogen
Ipsogen
Iquum
Iris Molecular Diagnostics
Janssen Biotech
Janssen Diagnostics
LabCorp
Life Technologies
Luminex Corporation
Manostring Technologies
Merck
Miltenyi Biotec
Mylan
Myraqa
Myriad Genetics
NextBio
Oncolys BioPharma
Ono Pharmaceutical
Oxford Nanopore
Pacific Biosciences
Pathway Genomics
Pathway Pharmaceuticals
Pensabio
PerkinElmer
Pfizer
Prosigna
Qiagen
Qiagen Marseille
Quest Diagnostics
Quidel
RainDance Technologies
Rarecells
Roche Diagnostics
Sakura
Sanofi
ScreenCell
Siemens
Signature Diagnostics
Silicon Biosystems
SRI Biosciences
Stratos Genomics
Sysmex
Takeda
Thermo Fisher Scientific
Twist Bioscience
Ventana Medical Systems
Verinata Health
Vysis
Actionable Genome Consortium
Arizona State University
Carnegie Mellon University
First Oncology Research and Advisory Center
Genomics England
Institut Curie
MGH Cancer Center
Massachusetts Institute of Technology
National Cancer Center
Paris-Descartes University
Pennsylvania State University
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
Or click on https://goo.gl/oH18Fc